Efficacy of Sofosbuvir Plus Ribavirin with and without Pegylated Interferon in Management of Egyptian Chronic Hepatitis C Patients

Al Dahshan, Magdy; Zaky, Samy; Seif El-Din, Sameh Mohamed; Ali, Mohammed Salah; Nouh, Alaa; Hammad, Radi

doi:10.21608/aeji.2017.17790

Efficacy of Sofosbuvir Plus Ribavirin with and without Pegylated Interferon in Management of Egyptian Chronic Hepatitis C Patients

Document Type : Original Article

Authors

¹ Internal Medicine Department, Al-Azhar University, Cairo, Egypt

² Tropical Medicine Department, Al-Azhar University, Damita, Egypt

³ Internal Medicine Department, National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt

⁴ Tropical Medicine Department, Menoufia University, Menoufia, Egypt

10.21608/aeji.2017.17790

Abstract

Background and study aim: Egypt is one of the highest prevalence of antibodies to hepatitis C virus (HCV) in the world, estimated nationally at 6.3%. Applying best treatment protocol has a great impact on the national disease burden. DAAs open the door to decrease HCV prevalence as well as to treat infected subjects.
Patients and Methods: In this study 1000 patients treated by Pegylated interferon, Sofosbuvir and weight adjusted Ribavirin. Another group of 1000 patients treated by Sofosbuvir and weight adjusted Ribavirin.
Results: Two groups showed sustained virological response : 90.1% and 72.3% respectively. Both groups approved that previous treatment status and viral load has no impact on response prediction. Both showed that males are more likely to respond than females.
Conclusion: Addition of Direct Acting Antivirals (DAAs), like sofosbovir, to the standard treatment with interferon and ribavirin improved the duration of the treatment and the sustained virological response (SVR). Treating of cirrhotics byPEGINF+SOF+RBV and SOF+RBV leads to decrease success rates. Validation of SVR once will be a golden rule.

Keywords

Main Subjects